We are focused on bettering lives

Where we began

In early 2017 Dr. Neil Fleshner, a practicing urologist in Toronto, accompanied his first prostate cancer patient to Germany for an experimental new cancer treatment - radioligand therapy. The treatment was not available anywhere in North America – Dr. Fleshner and his patient had to travel to Germany, at significant expense, for it to be administered. Wanting to improve patient access to these advancements in cancer care, Dr. Fleshner began thinking about how a team could be assembled to build the infrastructure necessary to bring these innovative therapeutics to more people.

This seed of an idea resulted in the formation of POINT Biopharma.

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. In addition to our exciting pipeline of radioligand molecules for a variety of cancers, we also operate our radiopharmaceutical production facility in Indianapolis, Indiana which is capable of servicing all of North America as well as many global locations.

Two POINT employees in a lab.

Our leadership team

We are a diverse group with a shared goal: to transform lives touched by cancer. With collaboration and innovation, we will change health care, for good.

Joe McCann, Ph.D.

Joe McCann, Ph.D.

Chief Executive Officer
Bill Demers, FCPA, BBA

Bill Demers, FCPA, BBA

Chief Financial Officer
Justyna Kelly, M.Sc.

Justyna Kelly, M.Sc.

Chief Operating Officer
Neil Fleshner, M.D.

Neil Fleshner, M.D.

Chief Medical Officer
Ari Shomair, HBA

Ari Shomair, HBA

Chief of Staff
Jessica Jensen, MPH

Jessica Jensen, MPH

EVP Clinical Development
Myra Rosario Herrle, Ph.D.

Myra Rosario Herrle, Ph.D.

EVP Regulatory Affairs
Chris Horvath, M.Sc. MBA

Chris Horvath, M.Sc. MBA

EVP Commercial
Matthew Vincent, Ph.D.

Matthew Vincent, Ph.D.

SVP Business Development

Our Board of Directors

More information regarding our board of directors is accessible in the investor relations section.

Come innovate with POINT.

We are working at the forefront of change. We’re deeply focused on cancer and only cancer. That means you can focus on making a difference.